Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This review examines the current evidence for the use of temozolomide in the treatment of solid tumours. The possible molecular and clinical advantages of temozolomide are identified and the molecular mechanism of temozolomide resistance is explored. Attempts to maximise efficacy have led to manipulation of both dosage and drug scheduling and the evidence for the various strategies is reviewed. Finally, the potential role of combination therapy is considered.

Original publication

DOI

10.1016/j.critrevonc.2004.10.004

Type

Journal article

Journal

Crit Rev Oncol Hematol

Publication Date

03/2005

Volume

53

Pages

241 - 252

Keywords

Antineoplastic Combined Chemotherapy Protocols, Apoptosis, DNA Repair, Dacarbazine, Drug Administration Schedule, Humans, Neoplasms, Temozolomide, Treatment Outcome